In recent years, the field of immuno-oncology has become one of the most promising and fastest growing areas of cancer research with many drugs introduced in the market and many more in the pipeline of different pharmaceutical companies. Immuno-oncology has become a sub-specialty within oncology owing to its unique science and its potential for substantial and long-term clinical benefit. This success is based on progress in both preclinical and clinical development of first and second generation of therapeutics using different molecules and immune system that include Antibody drug conjugates, bispecific antibodies, immune checkpoint blockades, adoptive cellular therapy.
Despite the growth much more research is needed to understand the breadth of opportunities these new generations of immunotherapies represent.
Next Gen Immuno-Oncology Congress to be held on 14th and 15th March 2017 in London UK aims to bring academicians, researchers and scientist from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the growth of existing therapeutics and pave way for emerging next generation therapeutics. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced.
This content is blocked. Accept cookies to view the content.